Adria Carbo
Vice President & Head of Business Development Orca Bio
Seminars
Wednesday 2nd December 2026
Highlighting Commercial Validation of Immune Reset Through Allogeneic Cell Therapy & Expanding Into Autoimmune Disease
9:30 am
- Examining the FDA approval of Orca-T and what this milestone signals for regulatory acceptance of next-generation allogeneic immune reset therapies
- Demonstrating how this transplant-replacement platform significantly reduces toxicity while preserving the curative potential of allogeneic hematopoietic stem cell transplantation
- Showcasing Orca-Q as the next-generation platform being advanced toward autoimmune disease, translating lessons from hematologic malignancies into severe autoimmune indications
Thursday 3rd December 2026
Audience Discussion: Modality Debate – Autologous vs Allogeneic vs In Vivo
9:00 am
- Debating which platform will dominate the autoimmune cell therapy landscape long-term
- Evaluating trade-offs between manufacturing control, patient convenience, safety, and efficacy
- Assessing whether ex vivo autologous approaches represent a transitional technology or enduring solution
